Europe Blau Syndrome Market - Industry Trends and Forecast to 2027
- DBMR961
- Pages: 120
- July 2020
- Total Views:1135
- Region : Global
- Data Bridge Market Research
- Market Research Report

Details
Europe Blau syndrome market is projected to register a healthy CAGR of 12.0% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation
Europe Blau Syndrome Market, By Type (Treatment and Diagnosis), Therapeutic Areas (Skin Rash and Inflammation), Route Of Administration (Oral, Parenteral, Topical and Others), End User (Hospitals, Diagnostic Centers, Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Direct Tender and Others), Country (Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands, Switzerland and Rest of Europe) Industry Trends & Forecast to 2027
Some of the major factors contributing to the growth of Europe Blau syndrome market are:
High adoption of biological therapies
Advancements in health care industry
Market Players:
The key market players for Europe Blau syndrome market are listed below:
Novartis AG
Pfizer Inc.
AbbVie Inc.
Amgen Inc.
Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)
Mylan N.V.
Hikma Pharmaceuticals PLC
Swedish Orphan Biovitrum AB
Alkem Labs.
Accord Healthcare
F. Hoffmann-La Roche Ltd
Amneal Pharmaceuticals LLC
Centogene AG
Oncodesign
Table Of Content
Scope
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE BLAU SYNDROME MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 THERAPEUTIC AREAS OF BLAU SYNDROME LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.10 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 EUROPE BLAU SYNDROME MARKET: REGULATIONS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 HIGH ADOPTION OF BIOLOGICAL THERAPIES
5.1.2 EMERGENCE OF DRUGS USED TO TREAT SYMPTOMS ASSOCIATED WITH BLAU SYNDROME
5.1.3 HIGH DEMAND OF DISEASE SPECIFIC TREATMENT
5.1.4 ADVANCEMENTS IN HEALTH CARE INDUSTRY
5.1.5 AVAILABILITY OF OFF LABEL DRUGS
5.2 RESTRAINTS
5.2.1 UNAVAILABILITY AND UNAFFORDABILITY OF EFFECTIVE TREATMENT
5.2.2 POOR DIAGNOSIS RATE IN SOME DEVELOPING COUNTRIES
5.2.3 LARGE NUMBER OF SIDE EFFECTS OF AVAILABLE DRUGS
5.3 OPPORTUNITIES
5.3.1 RISING DISPOSABLE INCOME
5.3.2 RISING STRATEGIC INITIATIVES BY PHARMACEUTICAL COMPANIES
5.3.3 EMERGING MARKETS
5.3.4 INCREASING RESEARCH AND DEVELOPMENT
5.4 CHALLENGES
5.4.1 LACK OF APPROVED DRUGS
5.4.2 HIGH COST ASSOCIATED WITH SYNDROME DIAGONSIS
5.4.3 LACK OF SKILLED RESOURCE FOR PERFORMING GENETIC TESTS
6 IMPACT OF COVID-19 PANDEMIC ON THE EUROPE BLAU SYNDROME MARKET
6.1 PRICE IMPACT
6.2 IMPACT ON DEMAND
6.3 IMPACT ON SUPPLY CHAIN
6.4 STRATEGIC DECISIONS FOR MANUFACTURERS
6.5 CONCLUSION
7 EUROPE BLAU SYNDROME MARKET, BY TYPE
7.1 OVERVIEW
7.2 TREATMENT
7.2.1 CORTICOSTEROIDS
7.2.1.1 PREDNISOLONE
7.2.1.2 COMBINATION CORTICOSTEROIDS
7.2.1.3 NAPROXEN
7.2.1.4 OTHERS
7.2.2 IMMUNOSUPPRESSANTS
7.2.2.1 METHOTREXATE
7.2.2.2 MYCOPHENOLATE MOFETIL
7.2.2.3 AZATHIOPRINE
7.2.2.4 OTHERS
7.2.3 TNF-? INHIBITORS
7.2.3.1 INFLIXIMAB
7.2.3.2 ADALIMUMAB
7.2.3.3 ETANERCEPT
7.2.3.4 OTHERS
7.2.4 OPTHALMIC MEDICATION
7.2.4.1 PREDNISOLONE ACETATE
7.2.4.2 TROPICAMIDE
7.2.4.3 OTHERS
7.2.5 INTERLEUKIN RECEPTOR
7.2.5.1 ANAKINRA
7.2.5.2 CANAKINUMAB
7.2.5.3 OTHERS
7.2.6 OTHERS
7.3 DIAGNOSIS
7.3.1 SCREENING
7.3.1.1 LAB TEST
7.3.1.1.1 BLOOD TEST
7.3.1.1.2 SALIVA TEST
7.3.1.1.3 OTHERS
7.3.1.2 IMAGING TEST
7.3.1.2.1 CT SCANS
7.3.1.2.2 ULTRASOUNDS
7.3.1.2.3 OTHERS
7.3.2 CONFIRMATORY TEST
7.3.2.1 SKIN BIOPSY
7.3.2.2 GENETIC TEST
7.3.2.3 OTHERS
8 EUROPE BLAU SYNDROME MARKET, BY THERAPEUTIC AREAS
8.1 OVERVIEW
8.2 SKIN RASH
8.3 INFLAMMATION
8.3.1 GRANULOMATOUS DERMATITIS
8.3.2 SYNOVITIS
8.3.3 UVEITIS
8.3.4 GRANULOMATOUS ARTHRITIS
8.3.5 CHRONIC ARTHRITIS
8.3.6 OTHERS
9 EUROPE BLAU SYNDROME MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL
9.2.1 TABLET
9.2.2 CAPSULE
9.2.3 OTHERS
9.3 PARENTERAL
9.3.1 INTRAVENOUS
9.3.2 SUBCUTANEOUS
9.3.3 OTHERS
9.4 TOPICAL
9.4.1 OINTMENT
9.4.2 SOLUTION
9.4.3 OTHERS
9.5 OTHERS
10 EUROPE BLAU SYNDROME MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 DIAGNOSTICS CENTERS
10.4 CLINICS
10.5 HOME HEALTHCARE
10.6 OTHERS
11 EUROPE BLAU SYNDROME MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 HOSPITAL PHARMACY
11.3 RETAIL PHARMACY
11.4 ONLINE PHARMACY
11.5 DIRECT TENDER
11.6 OTHERS
12 EUROPE BLAU SYNDROME MARKET, BY GEOGRAPHY
12.1 EUROPE
12.1.1 GERMANY
12.1.2 FRANCE
12.1.3 U.K.
12.1.4 ITALY
12.1.5 NETHERLANDS
12.1.6 SPAIN
12.1.7 RUSSIA
12.1.8 SWITZERLAND
12.1.9 TURKEY
12.1.10 AUSTRIA
12.1.11 NORWAY
12.1.12 HUNGARY
12.1.13 LITHUANIA
12.1.14 IRELAND
12.1.15 POLAND
12.1.16 REST OF EUROPE
13 EUROPE BLAU SYNDROME MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 SWOT
15 COMPANY PROFILES
15.1 NOVARTIS AG
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 AMGEN INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENTS
15.3 PFIZER INC.
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 JANSSEN PHARMACEUTICALS, INC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 ABBVIE INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENTS
15.6 ACCORD HEALTHCARE
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENTS
15.7 ALKEM LABS
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 AMNEAL PHARMACEUTICALS LLC
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENTS
15.9 CENTOGENE N.V.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.10 F. HOFFMANN-LA ROCHE LTD
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 FULGENT GENETICS
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 HIKMA PHARMACEUTICALS PLC
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.13 INVITAE CORPORATION
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 MYLAN N.V.
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENTS
15.15 ONCODESIGN
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 SALIX PHARMACEUTICALS (A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.17 SWEDISH ORPHAN BIOVITRUM AB (PUBL)
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENTS
15.18 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENTS
15.19 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
List Of Figure
LIST OF FIGURES
FIGURE 1 EUROPE BLAU SYNDROME MARKET: SEGMENTATION
FIGURE 2 EUROPE BLAU SYNDROME MARKET : DATA TRIANGULATION
FIGURE 3 EUROPE BLAU SYNDROME MARKET: DROC ANALYSIS
FIGURE 4 EUROPE BLAU SYNDROME MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE BLAU SYNDROME MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE BLAU SYNDROME MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE BLAU SYNDROME MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE BLAU SYNDROME MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE BLAU SYNDROME MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE BLAU SYNDROME MARKET: SEGMENTATION
FIGURE 11 HIGH ADOPTION OF BIOLOGICAL THERAPIES AND HIGH DEMAND OF DISEASE SPECIFIC TREATMENT IS DRIVING THE EUROPE BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 12 TREATMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE BLAU SYNDROME MARKET IN 2020 & 2027
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF EUROPE BLAU SYNDROME MARKET
FIGURE 14 EUROPE BLAU SYNDROME MARKET: BY TYPE, 2019
FIGURE 15 EUROPE BLAU SYNDROME MARKET: BY TYPE, 2019-2027 (USD THOUSAND)
FIGURE 16 EUROPE BLAU SYNDROME MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 17 EUROPE BLAU SYNDROME MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 EUROPE BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019
FIGURE 19 EUROPE BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019-2027 (USD THOUSAND)
FIGURE 20 EUROPE BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027)
FIGURE 21 EUROPE BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE
FIGURE 22 EUROPE TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 23 EUROPE TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD THOUSAND)
FIGURE 24 EUROPE TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 25 EUROPE TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 26 EUROPE BLAU SYNDROME MARKET: BY END USER, 2019
FIGURE 27 EUROPE BLAU SYNDROME MARKET: BY END USER, 2019-2027 (USD THOUSAND)
FIGURE 28 EUROPE BLAU SYNDROME MARKET: BY END USER, CAGR (2020-2027)
FIGURE 29 EUROPE BLAU SYNDROME MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 EUROPE BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 31 EUROPE BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND)
FIGURE 32 EUROPE BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 33 EUROPE BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 EUROPE BLAU SYNDROME MARKET: SNAPSHOT (2019)
FIGURE 35 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019)
FIGURE 36 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027)
FIGURE 37 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027)
FIGURE 38 EUROPE BLAU SYNDROME MARKET: BY TYPE (2020-2027)
FIGURE 39 EUROPE BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%)
Licence Rights
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Companies
Novartis AG
Pfizer Inc.
AbbVie Inc.
Amgen Inc.
Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)
Mylan N.V.
Hikma Pharmaceuticals PLC
Swedish Orphan Biovitrum AB
Alkem Labs.
Accord Healthcare
F. Hoffmann-La Roche Ltd
Amneal Pharmaceuticals LLC
Centogene AG
Oncodesign
Company Profile
Company Profile Title
Europe Blau syndrome market is projected to register a healthy CAGR of 12.0% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation
Europe Blau Syndrome Market, By Type (Treatment and Diagnosis), Therapeutic Areas (Skin Rash and Inflammation), Route Of Administration (Oral, Parenteral, Topical and Others), End User (Hospitals, Diagnostic Centers, Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Direct Tender and Others), Country (Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands, Switzerland and Rest of Europe) Industry Trends & Forecast to 2027
Some of the major factors contributing to the growth of Europe Blau syndrome market are:
High adoption of biological therapies
Advancements in health care industry
Market Players:
The key market players for Europe Blau syndrome market are listed below:
Novartis AG
Pfizer Inc.
AbbVie Inc.
Amgen Inc.
Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)
Mylan N.V.
Hikma Pharmaceuticals PLC
Swedish Orphan Biovitrum AB
Alkem Labs.
Accord Healthcare
F. Hoffmann-La Roche Ltd
Amneal Pharmaceuticals LLC
Centogene AG
Oncodesign
Scope
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE BLAU SYNDROME MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 THERAPEUTIC AREAS OF BLAU SYNDROME LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.10 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 EUROPE BLAU SYNDROME MARKET: REGULATIONS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 HIGH ADOPTION OF BIOLOGICAL THERAPIES
5.1.2 EMERGENCE OF DRUGS USED TO TREAT SYMPTOMS ASSOCIATED WITH BLAU SYNDROME
5.1.3 HIGH DEMAND OF DISEASE SPECIFIC TREATMENT
5.1.4 ADVANCEMENTS IN HEALTH CARE INDUSTRY
5.1.5 AVAILABILITY OF OFF LABEL DRUGS
5.2 RESTRAINTS
5.2.1 UNAVAILABILITY AND UNAFFORDABILITY OF EFFECTIVE TREATMENT
5.2.2 POOR DIAGNOSIS RATE IN SOME DEVELOPING COUNTRIES
5.2.3 LARGE NUMBER OF SIDE EFFECTS OF AVAILABLE DRUGS
5.3 OPPORTUNITIES
5.3.1 RISING DISPOSABLE INCOME
5.3.2 RISING STRATEGIC INITIATIVES BY PHARMACEUTICAL COMPANIES
5.3.3 EMERGING MARKETS
5.3.4 INCREASING RESEARCH AND DEVELOPMENT
5.4 CHALLENGES
5.4.1 LACK OF APPROVED DRUGS
5.4.2 HIGH COST ASSOCIATED WITH SYNDROME DIAGONSIS
5.4.3 LACK OF SKILLED RESOURCE FOR PERFORMING GENETIC TESTS
6 IMPACT OF COVID-19 PANDEMIC ON THE EUROPE BLAU SYNDROME MARKET
6.1 PRICE IMPACT
6.2 IMPACT ON DEMAND
6.3 IMPACT ON SUPPLY CHAIN
6.4 STRATEGIC DECISIONS FOR MANUFACTURERS
6.5 CONCLUSION
7 EUROPE BLAU SYNDROME MARKET, BY TYPE
7.1 OVERVIEW
7.2 TREATMENT
7.2.1 CORTICOSTEROIDS
7.2.1.1 PREDNISOLONE
7.2.1.2 COMBINATION CORTICOSTEROIDS
7.2.1.3 NAPROXEN
7.2.1.4 OTHERS
7.2.2 IMMUNOSUPPRESSANTS
7.2.2.1 METHOTREXATE
7.2.2.2 MYCOPHENOLATE MOFETIL
7.2.2.3 AZATHIOPRINE
7.2.2.4 OTHERS
7.2.3 TNF-? INHIBITORS
7.2.3.1 INFLIXIMAB
7.2.3.2 ADALIMUMAB
7.2.3.3 ETANERCEPT
7.2.3.4 OTHERS
7.2.4 OPTHALMIC MEDICATION
7.2.4.1 PREDNISOLONE ACETATE
7.2.4.2 TROPICAMIDE
7.2.4.3 OTHERS
7.2.5 INTERLEUKIN RECEPTOR
7.2.5.1 ANAKINRA
7.2.5.2 CANAKINUMAB
7.2.5.3 OTHERS
7.2.6 OTHERS
7.3 DIAGNOSIS
7.3.1 SCREENING
7.3.1.1 LAB TEST
7.3.1.1.1 BLOOD TEST
7.3.1.1.2 SALIVA TEST
7.3.1.1.3 OTHERS
7.3.1.2 IMAGING TEST
7.3.1.2.1 CT SCANS
7.3.1.2.2 ULTRASOUNDS
7.3.1.2.3 OTHERS
7.3.2 CONFIRMATORY TEST
7.3.2.1 SKIN BIOPSY
7.3.2.2 GENETIC TEST
7.3.2.3 OTHERS
8 EUROPE BLAU SYNDROME MARKET, BY THERAPEUTIC AREAS
8.1 OVERVIEW
8.2 SKIN RASH
8.3 INFLAMMATION
8.3.1 GRANULOMATOUS DERMATITIS
8.3.2 SYNOVITIS
8.3.3 UVEITIS
8.3.4 GRANULOMATOUS ARTHRITIS
8.3.5 CHRONIC ARTHRITIS
8.3.6 OTHERS
9 EUROPE BLAU SYNDROME MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL
9.2.1 TABLET
9.2.2 CAPSULE
9.2.3 OTHERS
9.3 PARENTERAL
9.3.1 INTRAVENOUS
9.3.2 SUBCUTANEOUS
9.3.3 OTHERS
9.4 TOPICAL
9.4.1 OINTMENT
9.4.2 SOLUTION
9.4.3 OTHERS
9.5 OTHERS
10 EUROPE BLAU SYNDROME MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 DIAGNOSTICS CENTERS
10.4 CLINICS
10.5 HOME HEALTHCARE
10.6 OTHERS
11 EUROPE BLAU SYNDROME MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 HOSPITAL PHARMACY
11.3 RETAIL PHARMACY
11.4 ONLINE PHARMACY
11.5 DIRECT TENDER
11.6 OTHERS
12 EUROPE BLAU SYNDROME MARKET, BY GEOGRAPHY
12.1 EUROPE
12.1.1 GERMANY
12.1.2 FRANCE
12.1.3 U.K.
12.1.4 ITALY
12.1.5 NETHERLANDS
12.1.6 SPAIN
12.1.7 RUSSIA
12.1.8 SWITZERLAND
12.1.9 TURKEY
12.1.10 AUSTRIA
12.1.11 NORWAY
12.1.12 HUNGARY
12.1.13 LITHUANIA
12.1.14 IRELAND
12.1.15 POLAND
12.1.16 REST OF EUROPE
13 EUROPE BLAU SYNDROME MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 SWOT
15 COMPANY PROFILES
15.1 NOVARTIS AG
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 AMGEN INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENTS
15.3 PFIZER INC.
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 JANSSEN PHARMACEUTICALS, INC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 ABBVIE INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENTS
15.6 ACCORD HEALTHCARE
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENTS
15.7 ALKEM LABS
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 AMNEAL PHARMACEUTICALS LLC
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENTS
15.9 CENTOGENE N.V.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.10 F. HOFFMANN-LA ROCHE LTD
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 FULGENT GENETICS
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 HIKMA PHARMACEUTICALS PLC
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.13 INVITAE CORPORATION
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 MYLAN N.V.
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENTS
15.15 ONCODESIGN
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 SALIX PHARMACEUTICALS (A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.17 SWEDISH ORPHAN BIOVITRUM AB (PUBL)
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENTS
15.18 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENTS
15.19 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
List Of Figure
LIST OF FIGURES
FIGURE 1 EUROPE BLAU SYNDROME MARKET: SEGMENTATION
FIGURE 2 EUROPE BLAU SYNDROME MARKET : DATA TRIANGULATION
FIGURE 3 EUROPE BLAU SYNDROME MARKET: DROC ANALYSIS
FIGURE 4 EUROPE BLAU SYNDROME MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE BLAU SYNDROME MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE BLAU SYNDROME MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE BLAU SYNDROME MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE BLAU SYNDROME MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE BLAU SYNDROME MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE BLAU SYNDROME MARKET: SEGMENTATION
FIGURE 11 HIGH ADOPTION OF BIOLOGICAL THERAPIES AND HIGH DEMAND OF DISEASE SPECIFIC TREATMENT IS DRIVING THE EUROPE BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 12 TREATMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE BLAU SYNDROME MARKET IN 2020 & 2027
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF EUROPE BLAU SYNDROME MARKET
FIGURE 14 EUROPE BLAU SYNDROME MARKET: BY TYPE, 2019
FIGURE 15 EUROPE BLAU SYNDROME MARKET: BY TYPE, 2019-2027 (USD THOUSAND)
FIGURE 16 EUROPE BLAU SYNDROME MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 17 EUROPE BLAU SYNDROME MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 EUROPE BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019
FIGURE 19 EUROPE BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019-2027 (USD THOUSAND)
FIGURE 20 EUROPE BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027)
FIGURE 21 EUROPE BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE
FIGURE 22 EUROPE TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 23 EUROPE TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD THOUSAND)
FIGURE 24 EUROPE TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 25 EUROPE TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 26 EUROPE BLAU SYNDROME MARKET: BY END USER, 2019
FIGURE 27 EUROPE BLAU SYNDROME MARKET: BY END USER, 2019-2027 (USD THOUSAND)
FIGURE 28 EUROPE BLAU SYNDROME MARKET: BY END USER, CAGR (2020-2027)
FIGURE 29 EUROPE BLAU SYNDROME MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 EUROPE BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 31 EUROPE BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND)
FIGURE 32 EUROPE BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 33 EUROPE BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 EUROPE BLAU SYNDROME MARKET: SNAPSHOT (2019)
FIGURE 35 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019)
FIGURE 36 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027)
FIGURE 37 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027)
FIGURE 38 EUROPE BLAU SYNDROME MARKET: BY TYPE (2020-2027)
FIGURE 39 EUROPE BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%)
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Companies
Novartis AG
Pfizer Inc.
AbbVie Inc.
Amgen Inc.
Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)
Mylan N.V.
Hikma Pharmaceuticals PLC
Swedish Orphan Biovitrum AB
Alkem Labs.
Accord Healthcare
F. Hoffmann-La Roche Ltd
Amneal Pharmaceuticals LLC
Centogene AG
Oncodesign